4.7 Article

HIV-1 Dynamics and Coreceptor Usage in Maraviroc-Treated Patients with Ongoing Replication

Journal

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Volume 57, Issue 2, Pages 930-935

Publisher

AMER SOC MICROBIOLOGY
DOI: 10.1128/AAC.02159-12

Keywords

-

Funding

  1. Agence Nationale de Recherches sur le SIDA et les Hepatites Virales (ANRS
  2. Paris, France)
  3. Pfizer
  4. European Community's Seventh Framework Programme under the project Collaborative HIV and Anti-HIV Drug Resistance Network (CHAIN) [223131]

Ask authors/readers for more resources

There is evidence that HIV-1 evolution under maraviroc (MVC) pressure can lead to the selection of either X4-tropic variants and/or R5-tropic, MVC-resistant isolates. However, the viral dynamics of HIV-1 variants in patients with virological failure (VF) on MVC-containing regimens remain poorly studied. Here, we investigated the V3 loop evolution of HIV-1 on MVC in relation to coreceptor usage and the nature of HIV-1 quasispecies before MVC therapy using bulk population sequences and ultradeep sequencing. The majority of patients had no detectable minority X4 variant at baseline. The evolution of tropism was followed up until VF and showed three possibilities for viral evolution in these patients: emergence of preexisting X4 variants, de novo selection of R5 variants presenting V3 loop mutations, or replication of R5 variants without selection of known mutations.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available